학술논문
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
Document Type
Review Article
Author
Source
In Critical Reviews in Oncology / Hematology April 2024 196
Subject
Language
ISSN
1040-8428